Neuroinflammation in Huntington’s disease: From animal models to clinical therapeutics
Open accessThe DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Abstract
Huntington’s disease (HD) is a progressive neurodegenerative disease characterized by preferential loss of neurons in the striatum in patients, which leads to motor and cognitive impairments and death that often occurs 10-15 years after the onset of symptoms. The expansion of a glutamine repeat (>36 glutamines) in the N-terminal region of huntingtin (HTT) has been defined as the cause of HD, but the mechanism underlying neuronal death remains unclear. Multiple mechanisms, including inflammation, may jointly contribute to HD pathogenesis. Altered inflammation response is evident even before the onset of classical symptoms of HD. In this review, we summarize the current evidence on immune and inflammatory changes, from HD animal models to clinical phenomenon of patients with HD. The understanding of the impact of inflammation on HD would help develop novel strategies to treat HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition to direct neuronal toxicity, HD pathogenesis is accompanied by significant neuroinflammation [192]. Brains impacted with HD exhibit increased microglial activation and elevated pro-inflammatory cytokine levels, including IL-6 and TNF-α [193,194].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [194]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366 · cited 1×
“Expansions varying from 36 to 39 CAG repeats may also result in HD, but with incomplete penetrance (1).”
BackgroundThe TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073 · cited 2×
“The R6/1 and R6/2 transgenic mice were the first transgenic model developed to study HD, which express exon 1 of the human HD gene with around 115 and 150 CAG repeats respectively (16).”
BackgroundGlutamine Repeats and Neurodegeneration
Zoghbi, H. Y., & Orr, H. T. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.217 · Cited by 1,309 · cited 1×
“The CAG repeat expansion encodes an expanded polyglutamine (polyQ) tract in mutant HTT that elicits neuronal loss in HD (4).”
BackgroundHistone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., et al. (2001) · Nature · doi:10.1038/35099568 · Cited by 1,228 · cited 1×
“In vivo experiments have revealed that the ectopic overexpression of mutant human HTT (exon 1 with expanded CAG repeats) in the neural tissue of transgenic flies causes neurodegeneration (12, 13).”
BackgroundHarrison, J. K., Jiang, Y., Chen, S., Xia, Y., Maciejewski, D., McNamara, R. K., Streit, W. J., Salafranca, M. N., Adhikari, S., Thompson, D. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10896 · Cited by 1,176 · cited 6×
“Furthermore, administering CX3CL1 protein was able to rescue R6/1 mice from long-term depression.”
BackgroundInfluentialDown-Regulation of the Macrophage Lineage Through Interaction with OX2 (CD200)
Hoek, R. M., Ruuls, S. R., Murphy, C. A., Wright, G. J., Goddard, R., Zurawski, S. M., Blom, B., Homola, M. E., Streit, W. J., Brown, M. H., et al. (2000) · Science · doi:10.1126/science.290.5497.1768 · Cited by 1,022 · cited 1×
“Neuroinflammation can be modulated by neuron-glial signaling through various soluble factors, such as cluster of differentiation CD22 (80), CD47 (81), CD200 (82, 83), the family of CD300 receptors (84) and CX3CL1 (85).”
BackgroundCarter, R. J., Lione, L. A., Humby, T., Mangiarini, L., Mahal, A., Bates, G. P., Dunnett, S. B., & Morton, A. J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-08-03248.1999 · Cited by 947
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease
Slow, E. J. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg169 · Cited by 800 · cited 2×
“Secondly, full-length transgenic mouse models carry mutant HTT in a yeast artificial chromosome (YAC) or bacterial artificial chromosome (BAC), which present a slow progression of the disease with comparable neuropathology and motor-related behavior changes (17, 18).”
BackgroundBjörkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R. V., Benn, C. L., Soulet, D., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080178 · Cited by 650 · cited 7×
“The altered immune system function, not only in the CNS but also peripherally, has been implicated in HD pathogenesis (6, 37).”
BackgroundInfluentialGray, M., Shirasaki, D. I., Cepeda, C., Andre, V. M., Wilburn, B., Lu, X.-H., Tao, J., Yamazaki, I., Li, S.-H., Sun, Y. E., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0857-08.2008 · Cited by 613 · cited 1×
“Secondly, full-length transgenic mouse models carry mutant HTT in a yeast artificial chromosome (YAC) or bacterial artificial chromosome (BAC), which present a slow progression of the disease with comparable neuropathology and motor-related behavior changes (17, 18).”
BackgroundSelf-citationJunker, A., Krumbholz, M., Eisele, S., Mohan, H., Augstein, F., Bittner, R., Lassmann, H., Wekerle, H., Hohlfeld, R., & Meinl, E. (2009) · Brain · doi:10.1093/brain/awp300 · Cited by 595 · cited 1×
“Neuroinflammation can be modulated by neuron-glial signaling through various soluble factors, such as cluster of differentiation CD22 (80), CD47 (81), CD200 (82, 83), the family of CD300 receptors (84) and CX3CL1 (85).”
BackgroundNeurological abnormalities in a knock-in mouse model of Huntington's disease
Lin, C.-H. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.2.137 · Cited by 592 · cited 1×
“While Hdh150Q knock-in mice at 27-30 weeks of age also did not show intense GFAP immunoreact iv i ty , a s ignificant increase in GFAP immunoreactivity was found in the striatum of Hdh mice at 14 months of age, as reported previously (26, 50).”
Self-citationAnimal models of neurodegenerative diseases
Dawson, T. M., Golde, T. E., & Lagier-Tourenne, C. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0236-8 · Cited by 576
Huntingtin–protein interactions and the pathogenesis of Huntington's disease
Li, S.-H., & Li, X.-J. (2004) · Trends in Genetics · doi:10.1016/j.tig.2004.01.008 · Cited by 548
Self-citationEarly and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain
Sapp, E., Kegel, K. B., Aronin, N., Hashikawa, T., Uchiyama, Y., Tohyama, K., Bhide, P. G., Vonsattel, J. P., & Difiglia, M. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.2.161 · Cited by 540 · cited 1×
“Pathological processes underlying HD, such as excitotoxicity or oxidative stress, induce the morphological change of microglia by a constant expression of inflammatory mediators (7).”
BackgroundMenalled, L. B., Sison, J. D., Dragatsis, I., Zeitlin, S., & Chesselet, M. (2003) · Journal of Comparative Neurology · doi:10.1002/cne.10776 · Cited by 536
Towards a transgenic model of Huntington’s disease in a non-human primate
Yang, S.-H., Cheng, P.-H., Banta, H., Piotrowska-Nitsche, K., Yang, J.-J., Cheng, E. C. H., Snyder, B., Larkin, K., Liu, J., Orkin, J., et al. (2008) · Nature · doi:10.1038/nature06975 · Cited by 501 · cited 2×
“Despite their early death, some transgenic monkeys developed key clinical HD features including dystonia, chorea, and seizure (70).”
BackgroundMethodSelf-citationExpression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity
Shin, J.-Y., Fang, Z.-H., Yu, Z.-X., Wang, C.-E., Li, S.-H., & Li, X.-J. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200508072 · Cited by 477 · cited 1×
“For example, the mutant HTT expressed in glial cells, primarily astrocytes in HDmouse models, could reduce their neuroprotective function (9, 10).”
BackgroundSelf-citationMenalled, L. B., Kudwa, A. E., Miller, S., Fitzpatrick, J., Watson-Johnson, J., Keating, N., Ruiz, M., Mushlin, R., Alosio, W., McConnell, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049838 · Cited by 469
Wheeler, V. C. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.4.503 · Cited by 469 · cited 1×
“In HD KI mice expressing shorter CAG repeats (HdhQ92 or HTTQ111), no gliosis was found up to 17-18 months of age (55, 56).”
BackgroundSelf-citationMicroglial activation correlates with severity in Huntington disease: A clinical and PET study
Pavese, N., Gerhard, A., Tai, Y. F., Ho, A. K., Turkheimer, F., Barker, R. A., Brooks, D. J., & Piccini, P. (2006) · Neurology · doi:10.1212/01.wnl.0000222734.56412.17 · Cited by 462
Novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity
Qi, X., Qvit, N., Su, Y.-C., & Mochly-Rosen, D. (2012) · Journal of Cell Science · doi:10.1242/jcs.114439 · Cited by 439 · cited 1×
“Frontiers in Immunology 03 Interestingly, treatment with P110 (a selective peptide inhibitor, of excessive mitochondrial fission) for 8 weeks was efficient in reducing the levels of these inflammatory levels to the level in WT mice (39, 40).”
BackgroundNonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
Turmaine, M., Raza, A., Mahal, A., Mangiarini, L., Bates, G. P., & Davies, S. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.110078997 · Cited by 430 · cited 1×
“In 17week-old R6/2 mouse model, reactive astrocytes with processes enveloping degenerating neurons was seen, though no accompanying inflammatory response or increased macrophages and microglia was observed (53).”
BackgroundWang, X., Zhu, S., Drozda, M., Zhang, W., Stavrovskaya, I. G., Cattaneo, E., Ferrante, R. J., Kristal, B. S., & Friedlander, R. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1832501100 · Cited by 407 · cited 1×
“R6/2 mice were administered with the anti-inflammatory tetracycline minocycline showed improvements in behavioral and neuropathological deficits (89, 90), which is also supported by an excitotoxic rat model of HD (91).”
Murphy, K. P. S. J., Carter, R. J., Lione, L. A., Mangiarini, L., Mahal, A., Bates, G. P., Dunnett, S. B., & Morton, A. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-13-05115.2000 · Cited by 398
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
Palazuelos, J., Aguado, T., Pazos, M. R., Julien, B., Carrasco, C., Resel, E., Sagredo, O., Benito, C., Romero, J., Azcoitia, I., et al. (2009) · Brain · doi:10.1093/brain/awp239 · Cited by 382
Beyond the brain: widespread pathology in Huntington's disease
van der Burg, J. M., Björkqvist, M., & Brundin, P. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70178-4 · Cited by 363
Neuron–glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage
Sheridan, G. K., & Murphy, K. J. (2013) · Open Biology · doi:10.1098/rsob.130181 · Cited by 337 · cited 1×
“CX3CL1 produced in neurons is the sole member of the CX3C family of chemokines (86), and it is known that CX3CL1 is the only ligand binding to CX3CR1, a 7 transmembrane domain class A Gprotein coupled receptor that is expressed in microglia, monocytes, natural killer cells (NK), T cells and smooth muscle cells (87).”
BackgroundYan, S., Tu, Z., Liu, Z., Fan, N., Yang, H., Yang, S., Yang, W., Zhao, Y., Ouyang, Z., Lai, C., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.005 · Cited by 337 · cited 2×
“Quantification of the number of different types of cells revealed that the KI striatum had the most severe loss of NeuN-positive cells and the highest increase in glial cell numbers, which was not observed in the age-matched HD KI mouse (66, 67).”
BackgroundSelf-citationMutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors
Crotti, A., Benner, C., Kerman, B. E., Gosselin, D., Lagier-Tourenne, C., Zuccato, C., Cattaneo, E., Gage, F. H., Cleveland, D. W., & Glass, C. K. (2014) · Nature Neuroscience · doi:10.1038/nn.3668 · Cited by 333 · cited 1×
“However, in 18-20 months old Hdh175/175 mouse, the expression of full-length mHTT in microglia was able to promote pro-inflammatory transcription (57).”
BackgroundEarly Loss of Neostriatal Striosome Neurons in Huntingtonʼs Disease
HEDREEN, J. C., & FOLSTEIN, S. E. (1995) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199501000-00013 · Cited by 326
Controlled clinical trial of cannabidiol in Huntington's disease
Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., & Schram, K. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90386-g · Cited by 320 · cited 1×
“However, clinical outcomes did not show the significant improvement (93).”
BackgroundSensory lesioning induces microglial synapse elimination via ADAM10 and fractalkine signaling
Gunner, G., Cheadle, L., Johnson, K. M., Ayata, P., Badimon, A., Mondo, E., Nagy, M. A., Liu, L., Bemiller, S. M., Kim, K.-W., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0419-y · Cited by 317 · cited 1×
“It appears that striatal synaptic plasticity dysfunction in pre-symptomatic R6/1 mice is caused by a reduction in CX3CL1 (30), which is consistent with the previous research that CX3CL1 regulates microglia engulfment of synapse (31).”
ResultSinghrao, S. K., Neal, J. W., Morgan, B. P., & Gasque, P. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7170 · Cited by 316 · cited 1×
“also found the complement activation, and increased mRNA levels of complement proteins in HD brains (79).”
BackgroundTryptophan metabolism and oxidative stress in patients with Huntington's disease
Stoy, N., Mackay, G. M., Forrest, C. M., Christofides, J., Egerton, M., Stone, T. W., & Darlington, L. G. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03070.x · Cited by 310
The kynurenine pathway and neurodegenerative disease
Maddison, D. C., & Giorgini, F. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.03.002 · Cited by 309 · cited 1×
“Additionally, quinolinic acid (QUIN) has been associated with neuroinflammation in various neurological diseases (32).”
BackgroundSimmons, D. A., Casale, M., Alcon, B., Pham, N., Narayan, N., & Lynch, G. (2007) · Glia · doi:10.1002/glia.20526 · Cited by 277 · cited 1×
“also reported that the Iba-1 positive cells did not obviously differ in both R6/2 and WT mice at the age of <7 weeks, but increased in R6/2 mice older than 8 weeks (54).”
BackgroundMutant Huntingtin Causes Context-Dependent Neurodegeneration in Mice with Huntington's Disease
Yu, Z.-X., Li, S.-H., Evans, J., Pillarisetti, A., Li, H., & Li, X.-J. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02193.2003 · Cited by 262 · cited 2×
“While Hdh150Q knock-in mice at 27-30 weeks of age also did not show intense GFAP immunoreact iv i ty , a s ignificant increase in GFAP immunoreactivity was found in the striatum of Hdh mice at 14 months of age, as reported previously (26, 50).”
BackgroundSelf-citationNeostriatal and cortical quinolinate levels are increased in early grade Huntington's disease
GUIDETTI, P., LUTHICARTER, R., AUGOOD, S., & SCHWARCZ, R. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.006 · Cited by 260 · cited 1×
“QUIN and 3-hydroxykynurenine (3-HK) are neurotoxic metabolites that are elevated in the cortex of HD patients at the early stages of disease progression (36).”
BackgroundThe CD300 molecules: an emerging family of regulators of the immune system
Borrego, F. (2013) · Blood · doi:10.1182/blood-2012-09-435057 · Cited by 251 · cited 1×
“Neuroinflammation can be modulated by neuron-glial signaling through various soluble factors, such as cluster of differentiation CD22 (80), CD47 (81), CD200 (82, 83), the family of CD300 receptors (84) and CX3CL1 (85).”
BackgroundStack, E. C., Kubilus, J. K., Smith, K., Cormier, K., Del Signore, S. J., Guelin, E., Ryu, H., Hersch, S. M., & Ferrante, R. J. (2005) · Journal of Comparative Neurology · doi:10.1002/cne.20680 · Cited by 246 · cited 1×
“Despite the wealth of different transgenic HD mice available currently, the R6/2 and YAC128 mouse strains are widely used to study many pathological aspects of HD (19).”
BackgroundThe Role of Microglia and Astrocytes in Huntington’s Disease
Palpagama, T. H., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00258 · Cited by 239
Huntington's Disease: Can Mice Lead the Way to Treatment?
Crook, Z. R., & Housman, D. (2011) · Neuron · doi:10.1016/j.neuron.2010.12.035 · Cited by 229
Dalrymple, A., Wild, E. J., Joubert, R., Sathasivam, K., Björkqvist, M., Petersén, Å., Jackson, G. S., Isaacs, J. D., Kristiansen, M., Bates, G. P., et al. (2007) · Journal of Proteome Research · doi:10.1021/pr0700753 · Cited by 228 · cited 11×
“It has been shown that the complement factors C1QC, C2, and C3 are also increased in CSF samples taken from living HD patients in comparison with controls (78).”
BackgroundInfluentialHickey, M. A., Kosmalska, A., Enayati, J., Cohen, R., Zeitlin, S., Levine, M. S., & Chesselet, M.-F. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.08.041 · Cited by 226
Distinct neuroinflammatory profile in post-mortem human Huntington's disease
Silvestroni, A., Faull, R. L. M., Strand, A. D., & Möller, T. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832e34ee · Cited by 203 · cited 2×
“Likewise, HD patients also exhibit increased expression of IL-6, IL-8, and matrix metalloproteinase-9 (MMP-9) in their cortex and cerebellum (73).”
BackgroundAn ovine transgenic Huntington's disease model
Jacobsen, J. C., Bawden, C. S., Rudiger, S. R., McLaughlan, C. J., Reid, S. J., Waldvogel, H. J., MacDonald, M. E., Gusella, J. F., Walker, S. K., Kelly, J. M., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq063 · Cited by 198 · cited 1×
“However, an HD transgenic sheep model (OVT73) was created, which does not exhibit many of the overt phenotypes observed in HD patients and was thought to be a model of prodromal or early-stage HD (65).”
BackgroundVan Raamsdonk, J. M., Murphy, Z., Slow, E. J., Leavitt, B. R., & Hayden, M. R. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi407 · Cited by 180
Knock-in mouse models of Huntington’s disease
Menalled, L. (2005) · NeuroRx · doi:10.1602/neurorx.2.3.465 · Cited by 178 · cited 1×
“In HD transgenic mice, the animals expressed a fulllength or a fragment of the mutant HTT gene in addition to the two normal copies of the endogenous mouse HTT gene (15).”
BackgroundNovel Targeted Therapies for Inflammatory Bowel Disease
Coskun, M., Vermeire, S., & Nielsen, O. H. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.014 · Cited by 178
Mott, R. T., Ait‐Ghezala, G., Town, T., Mori, T., Vendrame, M., Zeng, J., Ehrhart, J., Mullan, M., & Tan, J. (2004) · Glia · doi:10.1002/glia.20009 · Cited by 170
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
Guidetti, P., Bates, G. P., Graham, R. K., Hayden, M. R., Leavitt, B. R., MacDonald, M. E., Slow, E. J., Wheeler, V. C., Woodman, B., & Schwarcz, R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.02.011 · Cited by 166 · cited 1×
“Especially the 3-HK levels were elevated in the striatum, cortex and cerebellum in the R6/2 starting at 4 weeks of age significantly and selectively, and both 3-HK and QUIN levels were increased in the striatum and cortex in Hdh and Hdh at 15 months and YAC128 mouse at 8 months (35).”
BackgroundNomiyama, H., Osada, N., & Yoshie, O. (2012) · Genes to Cells · doi:10.1111/gtc.12013 · Cited by 165
Mutant Huntingtin in Glial Cells Exacerbates Neurological Symptoms of Huntington Disease Mice
Bradford, J., Shin, J.-Y., Roberts, M., Wang, C.-E., Sheng, G., Li, S., & Li, X.-J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.083287 · Cited by 164 · cited 1×
“For example, the mutant HTT expressed in glial cells, primarily astrocytes in HDmouse models, could reduce their neuroprotective function (9, 10).”
BackgroundSelf-citationLüesse, H., Schiefer, J., Spruenken, A., Puls, C., Block, F., & Kosinski, C. M. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00261-3 · Cited by 158
Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model
Chang, K., Wu, Y., Chen, Y., & Chen, C. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.09.011 · Cited by 156 · cited 2×
“Considering that pro-inflammatory cytokine IL-6 may actively influence the disease course in HD, an excessive IL-6 release was also detected in YAC128 mice at 12 months and R6/2 mice at 9, 11 and 13 weeks of age (6, 38).”
BackgroundThe Role of the Immune System in Huntington’s Disease
Ellrichmann, G., Reick, C., Saft, C., & Linker, R. A. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/541259 · Cited by 155 · cited 1×
“the periphery to the CNS or vice versa (5, 6).”
BackgroundKaye, J., Piryatinsky, V., Birnberg, T., Hingaly, T., Raymond, E., Kashi, R., Amit-Romach, E., Caballero, I. S., Towfic, F., Ator, M. A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607843113 · Cited by 140 · cited 3×
“HTT Huntingtin HD Huntington's disease polyQ polyglutamine CNS Central nervous system BBB Blood-brain barrier YAC Yeast artificial chromosome BAC Bacterial artificial chromosome LPS Lipopolysaccharides IL Interleukin TNF Tumor necrosis factor MCP-1 Monocyte chemoattractant protein-1 PSD-95 Postsynaptic density protein…”
BackgroundNeurobiology of Huntington's Disease
Sharp, A. H., & Ross, C. A. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0002 · Cited by 137
Sema4D/plexin‐B1 activates GSK‐3β through R‐Ras GAP activity, inducing growth cone collapse
Ito, Y., Oinuma, I., Katoh, H., Kaibuchi, K., & Negishi, M. (2006) · EMBO reports · doi:10.1038/sj.embor.7400737 · Cited by 137
Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease
Hsiao, H.-Y., Chiu, F.-L., Chen, C.-M., Wu, Y.-R., Chen, H.-M., Chen, Y.-C., Kuo, H.-C., & Chern, Y. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu151 · Cited by 134
Bouchard, J., Truong, J., Bouchard, K., Dunkelberger, D., Desrayaud, S., Moussaoui, S., Tabrizi, S. J., Stella, N., & Muchowski, P. J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4008-12.2012 · Cited by 133 · cited 1×
“In their work, treatment with the specific antibody in R6/2 mice reduced weight loss at late stages and partially rescued motor deficits on the rotarod performance as compared with the control IgG treatment (44).”
BackgroundAn emerging role for eotaxins in neurodegenerative disease
Huber, A. K., Giles, D. A., Segal, B. M., & Irani, D. N. (2018) · Clinical Immunology · doi:10.1016/j.clim.2016.09.010 · Cited by 133 · cited 1×
“In addition, CCL11 levels were positively correlated with standardized assessments of motor impairment while negatively correlated with functional scores (76, 77).”
BackgroundFranciosi, S., Ryu, J. K., Shim, Y., Hill, A., Connolly, C., Hayden, M. R., McLarnon, J. G., & Leavitt, B. R. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.09.003 · Cited by 127
Altered Gut Microbiota Related to Inflammatory Responses in Patients With Huntington’s Disease
Du, G., Dong, W., Yang, Q., Yu, X., Ma, J., Gu, W., & Huang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.603594 · Cited by 122 · cited 1×
“In contrast, no significant differences was observed in the plasma concentrations of IFN-g, IL-1b, IL-2, IL-6, IL-8, IL-10, IL-12p70, IL-13 or TNF-a in HD patients (74).”
BackgroundAbnormal peripheral chemokine profile in Huntington’s disease
Wild, E., Magnusson, A., Lahiri, N., Krus, U., Orth, M., Tabrizi, S. J., & Björkqvist, M. (2011) · PLoS Currents · doi:10.1371/currents.rrn1231 · Cited by 119 · cited 3×
“In particular, a significant elevation of chemokines (C-C motif) ligand (CCL)-2, CCL4, CCL11, CCL13, CCL26 has been detected in the plasma from HD patients (76).”
BackgroundCombination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice
Stack, E. C., Smith, K. M., Ryu, H., Cormier, K., Chen, M., Hagerty, S. W., Del Signore, S. J., Cudkowicz, M. E., Friedlander, R. M., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.11.002 · Cited by 114 · cited 1×
“R6/2 mice were administered with the anti-inflammatory tetracycline minocycline showed improvements in behavioral and neuropathological deficits (89, 90), which is also supported by an excitotoxic rat model of HD (91).”
A Transgenic Minipig Model of Huntington's Disease
Baxa, M., Hruska-Plochan, M., Juhas, S., Vodicka, P., Pavlok, A., Juhasova, J., Miyanohara, A., Nejime, T., Klima, J., Macakova, M., et al. (2013) · Journal of Huntington's Disease · doi:10.3233/jhd-130001 · Cited by 111 · cited 1×
“used transgenic HD minipig, which was generated by injecting lentiviral vectors carrying truncated mutant huntingtin genes that encode 124 glutamine repeats integrated into chromosome 1q24-q25 and transmitted through successive three generations (68), for investigating multiple cytokines (69).”
MethodSouthwell, A. L., Franciosi, S., Villanueva, E. B., Xie, Y., Winter, L. A., Veeraraghavan, J., Jonason, A., Felczak, B., Zhang, W., Kovalik, V., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.01.002 · Cited by 109
Early kynurenergic impairment in Huntington's Disease and in a transgenic animal model
Guidetti, P., Reddy, P. H., Tagle, D. A., & Schwarcz, R. M. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00956-3 · Cited by 97
Brain-specific Proteins Decline in the Cerebrospinal Fluid of Humans with Huntington Disease
Fang, Q., Strand, A., Law, W., Faca, V. M., Fitzgibbon, M. P., Hamel, N., Houle, B., Liu, X., May, D. H., Poschmann, G., et al. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800231-mcp200 · Cited by 92 · cited 1×
“It has been shown that the complement factors C1QC, C2, and C3 are also increased in CSF samples taken from living HD patients in comparison with controls (78).”
Ryu, J. K., Choi, H. B., & McLarnon, J. G. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.05.043 · Cited by 88 · cited 1×
“R6/2 mice were administered with the anti-inflammatory tetracycline minocycline showed improvements in behavioral and neuropathological deficits (89, 90), which is also supported by an excitotoxic rat model of HD (91).”
BackgroundDisease‐modifying effects of ganglioside GM1 in Huntington's disease models
Alpaugh, M., Galleguillos, D., Forero, J. P., Morales, L. C., Lackey, S. W. K., Kar, P., Pardo, A. D., Holt, A., Kerr, B. J., Todd, K. G., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707763 · Cited by 79
Minocycline safety and tolerability in Huntington disease
Huntington Study Group (2004) · Neurology · doi:10.1212/01.wnl.0000133403.30559.ff · Cited by 76 · cited 1×
“However, there was no effect on the UHDRS (Unified HD Rating Scale) scores, with no efficacy observed (92).”
BackgroundBone Marrow Transplantation Confers Modest Benefits in Mouse Models of Huntington's Disease
Kwan, W., Magnusson, A., Chou, A., Adame, A., Carson, M. J., Kohsaka, S., Masliah, E., Möller, T., Ransohoff, R., Tabrizi, S. J., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4846-11.2012 · Cited by 75 · cited 1×
“However, the elevation of IL-6 in serum of YAC128 mice occurred at 12 months of age whereas the level of IFN-g increased in serum samples from YAC128 mice were at 69 months old (41).”
BackgroundSchneider, J. S., Aras, R., Williams, C. K., Koprich, J. B., Brotchie, J. M., & Singh, V. (2019) · Scientific Reports · doi:10.1038/s41598-019-42847-x · Cited by 75
Aharoni, R., Saada, R., Eilam, R., Hayardeny, L., Sela, M., & Arnon, R. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.06.005 · Cited by 74 · cited 4×
“HTT Huntingtin HD Huntington's disease polyQ polyglutamine CNS Central nervous system BBB Blood-brain barrier YAC Yeast artificial chromosome BAC Bacterial artificial chromosome LPS Lipopolysaccharides IL Interleukin TNF Tumor necrosis factor MCP-1 Monocyte chemoattractant protein-1 PSD-95 Postsynaptic density protein…”
BackgroundInfluentialGarcia-Miralles, M., Hong, X., Tan, L. J., Caron, N. S., Huang, Y., To, X. V., Lin, R. Y., Franciosi, S., Papapetropoulos, S., Hayardeny, L., et al. (2016) · Scientific Reports · doi:10.1038/srep31652 · Cited by 66
Chan, A. W. S., Jiang, J., Chen, Y., Li, C., Prucha, M. S., Hu, Y., Chi, T., Moran, S., Rahim, T., Li, S., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122335 · Cited by 63 · cited 1×
“Interestingly, the 5-year-old transgenic HD monkeys expressing N-terminal HTT 509 amino acids with approximately 67-72Q under the human HTT promoter (71) exhibited increased pro-inflammatory cytokines and higher induction of immune pathway genes, such as inflammatory response factor IL-6, TNF-a, and CReactive Protein…”
BackgroundSelf-citationTräger, U., Andre, R., Magnusson-Lind, A., Miller, J. R. C., Connolly, C., Weiss, A., Grueninger, S., Silajdžić, E., Smith, D. L., Leavitt, B. R., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.10.012 · Cited by 63 · cited 1×
“These mouse models recapitulate altered cytokine profiles identified in HD patients, and therefore they could be used to model the immune phenotype (27).”
MethodLaquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model
Wilmes, A. T., Reinehr, S., Kühn, S., Pedreiturria, X., Petrikowski, L., Faissner, S., Ayzenberg, I., Stute, G., Gold, R., Dick, H. B., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1208-3 · Cited by 62
Potential biomarkers to follow the progression and treatment response of Huntington’s disease
Disatnik, M.-H., Joshi, A. U., Saw, N. L., Shamloo, M., Leavitt, B. R., Qi, X., & Mochly-Rosen, D. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160776 · Cited by 58 · cited 2×
“also measured the levels of inflammatory cytokines such as TNF and IL-6, the levels of both these cytokines were two times higher in the plasma of 13 weeks old R6/2 mice than WT mice (39).”
BackgroundPaldino, E., D’Angelo, V., Sancesario, G., & Fusco, F. R. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00293-z · Cited by 53
Pido-Lopez, J., Andre, R., Benjamin, A. C., Ali, N., Farag, S., Tabrizi, S. J., & Bates, G. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-29792-x · Cited by 51 · cited 1×
“revealed that the increased TNF-a and IL-12 levels in the striatum of 14-week-old R6/2 mice while IL-12 and IL-1b decreased in the cortex (28).”
BackgroundLaquinimod treatment in the R6/2 mouse model
Ellrichmann, G., Blusch, A., Fatoba, O., Brunner, J., Reick, C., Hayardeny, L., Hayden, M., Sehr, D., Winklhofer, K. F., Saft, C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04990-1 · Cited by 50
Reduced Fractalkine Levels Lead to Striatal Synaptic Plasticity Deficits in Huntington’s Disease
Kim, A., García-García, E., Straccia, M., Comella-Bolla, A., Miguez, A., Masana, M., Alberch, J., Canals, J. M., & Rodríguez, M. J. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00163 · Cited by 46 · cited 8×
“Recently, the fractalkine signaling axis has been explored in the 8-20 weeks old R6/1 HD mouse, and the expression levels of cx3cl1 have been significantly decreased (30), which may lead to an increase in synaptic pruning mediated by microglia, as the total density of PSD-95 puncta decreased and the density of PSD-95…”
BackgroundResultInfluentialA Friend in Need May Not be a Friend Indeed: Role of Microglia in Neurodegenerative Diseases
Kaushik, D. K., & Basu, A. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660170 · Cited by 45
CD200 modulates spinal cord injury neuroinflammation and outcome through CD200R1
Lago, N., Pannunzio, B., Amo‐Aparicio, J., López‐Vales, R., & Peluffo, H. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.06.002 · Cited by 45 · cited 1×
“Neuroinflammation can be modulated by neuron-glial signaling through various soluble factors, such as cluster of differentiation CD22 (80), CD47 (81), CD200 (82, 83), the family of CD300 receptors (84) and CX3CL1 (85).”
BackgroundGarcia‐Miralles, M., Yusof, N. A. B. M., Tan, J. Y., Radulescu, C. I., Sidik, H., Tan, L. J., Belinson, H., Zach, N., Hayden, M. R., & Pouladi, M. A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1393-1 · Cited by 45
Early Intrathecal T Helper 17.1 Cell Activity in Huntington Disease
von Essen, M. R., Hellem, M. N. N., Vinther‐Jensen, T., Ammitzbøll, C., Hansen, R. H., Hjermind, L. E., Nielsen, T. T., Nielsen, J. E., & Sellebjerg, F. (2020) · Annals of Neurology · doi:10.1002/ana.25647 · Cited by 45 · cited 2×
“This skewing further favors a pro-inflammatory environment in the CSF of HTT mutation carriers (75).”
BackgroundBlennow, K., Davidsson, P., Wallin, A., Frcdman, P., Gottfries, C. G., Månsson, J., & Svennerholm, L. T. (1992) · Aging Clinical and Experimental Research · doi:10.1007/bf03324111 · Cited by 43
Interleukin-6 deficiency exacerbates Huntington’s disease model phenotypes
Wertz, M. H., Pineda, S. S., Lee, H., Kulicke, R., Kellis, M., & Heiman, M. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00379-3 · Cited by 43 · cited 1×
“Based on a single nuclear RNA sequencing of striatal cell types, it was evident that IL-6 deficiency affected normal regulation of various genes associated with synaptic function, as well as the BDNF receptor Ntrk2 (45).”
BackgroundGM1 Ganglioside in the Treatment of Parkinson's Diseasea
Schneider, J. S. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb09688.x · Cited by 42
Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis
Varrin-Doyer, M., Zamvil, S. S., & Schulze-Topphoff, U. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.04.002 · Cited by 42
Immunotherapies in Huntington's disease and α-Synucleinopathies
Fatoba, O., Ohtake, Y., Itokazu, T., & Yamashita, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00337 · Cited by 42
Reiner, A. J., Mar, N. D., Deng, Y., Meade, C. A., Sun, Z., & Goldowitz, D. (2007) · The Journal of Comparative Neurology · doi:10.1002/cne.21515 · Cited by 40
Katsumoto, A., de Miranda, A. S., Butovsky, O., Teixeira, A. L., Ransohoff, R. M., & Lamb, B. T. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1075-y · Cited by 40 · cited 1×
“Thus, the therapeutic effect of LAQ is therefore thought to be due to an anti-inflammation effect (98, 103).”
BackgroundValeková, I., Jarkovská, K., Kotrčová, E., Bucci, J., Ellederová, Z., Juhás, Š., Motlík, J., Gadher, S. J., & Kovářová, H. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.02.012 · Cited by 36
Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons
Ehrnhoefer, D. E., Caron, N. S., Deng, Y., Qiu, X., Tsang, M., & Hayden, M. R. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.06.008 · Cited by 34
Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake
Gentile, A., Musella, A., Vito, F. D., Fresegna, D., Bullitta, S., Rizzo, F. R., Centonze, D., & Mandolesi, G. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1048-6 · Cited by 34
Kovalenko, M. V., Milnerwood, A. J., Giordano, J. V., Claire, J. S., Guide, J. R., Stromberg, M., Gillis, T., Sapp, E., DiFiglia, M., MacDonald, M. E., et al. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-170282 · Cited by 34 · cited 1×
“In HD KI mice expressing shorter CAG repeats (HdhQ92 or HTTQ111), no gliosis was found up to 17-18 months of age (55, 56).”
BackgroundPhosphorylation of myelin regulatory factor by PRKG2 mediates demyelination in Huntington's disease
Yin, P., Liu, Q., Pan, Y., Yang, W., Yang, S., Wei, W., Chen, X.-X., Hong, Y., Bai, D., Li, X., et al. (2020) · EMBO Reports · doi:10.15252/embr.201949783 · Cited by 33
Self-citationChandrasekaran, S., & Bonchev, D. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.02.001 · Cited by 31 · cited 1×
“Interestingly, CX3CL1 was also found to be an important novel factor in HD pathogenesis and survival following a network analysis of microarray data from human post-mortem tissue (88).”
BackgroundIncreased irritability, anxiety, and immune reactivity in transgenic Huntington’s disease monkeys
Raper, J., Bosinger, S. E., Johnson, Z., Tharp, G. K., Moran, S. P., & Chan, A. W. S. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.07.004 · Cited by 31 · cited 3×
“HTT Huntingtin HD Huntington's disease polyQ polyglutamine CNS Central nervous system BBB Blood-brain barrier YAC Yeast artificial chromosome BAC Bacterial artificial chromosome LPS Lipopolysaccharides IL Interleukin TNF Tumor necrosis factor MCP-1 Monocyte chemoattractant protein-1 PSD-95 Postsynaptic density protein…”
BackgroundGodavarthi, S. K., Narender, D., Mishra, A., Goswami, A., Rao, S. N. R., Nukina, N., & Jana, N. R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05823.x · Cited by 29 · cited 1×
“However, the Iba-1 immunostaining did not reveal any significant increase in the numbers of microglia in the cortex and striatum of R6/2 mice at 12 weeks, an age when these mice show severe symptoms (29).”
BackgroundMorphometric Analysis of Huntington’s Disease Neurodegeneration in Drosophila
Song, W., Smith, M. R., Syed, A., Lukácsovich, T., Barbaro, B. A., Purcell, J. M., Bornemann, D. J., Burke, J., & Marsh, J. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-438-8_3 · Cited by 27 · cited 1×
“In vivo experiments have revealed that the ectopic overexpression of mutant human HTT (exon 1 with expanded CAG repeats) in the neural tissue of transgenic flies causes neurodegeneration (12, 13).”
BackgroundPurushothaman, B., & Sumathi, T. (2021) · Neuroscience Research · doi:10.1016/j.neures.2021.08.003 · Cited by 27
Pido-Lopez, J., Tanudjojo, B., Farag, S., Bondulich, M.-K., Andre, R., Tabrizi, S. J., & Bates, G. P. (2019) · Scientific Reports · doi:10.1038/s41598-019-43627-3 · Cited by 26
Quantification of Huntington’s Disease Related Markers in the R6/2 Mouse Model
Etxeberria-Rekalde, E., Alzola-Aldamizetxebarria, S., Flunkert, S., Isabella, H., Daurer, M., Neddens, J., & Hutter‐Paier, B. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.617229 · Cited by 25
Gatto, R. G., Weissmann, C., Amin, M., Angeles-López, Q. D., García‐Lara, L., Castellanos, L. C. S., Deyoung, D., Segovia, J., Mareci, T. H., Uchitel, O. D., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.02.006 · Cited by 25 · cited 1×
“found that the neuroinflammatory processes with activated astrocyte GFAP occurred in the 11- and 30-week-old R6/1 mice (52).”
BackgroundPrados, M. E., Correa-Sáez, A., Unciti-Broceta, J. D., Garrido‐Rodríguez, M., Jiménez‐Jiménez, C., Mazzone, M., Minassi, A., Appendino, G., Calzado, M. A., & Muñóz, E. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01089-4 · Cited by 24
Transgenic Mouse Models and Human Neurodegenerative Disorders
Deng, H., & Siddique, T. (2000) · Archives of Neurology · doi:10.1001/archneur.57.12.1695 · Cited by 21
Expression of Human Mutant Huntingtin Protein in Drosophila Hemocytes Impairs Immune Responses
Lin, Y.-H., Maaroufi, H. O., Ibrahim, E., Kučerová, L., & Žurovec, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02405 · Cited by 20 · cited 3×
“However, there was limited work on neuroinflammation in Drosophila model of HD. Lin et al. observed that the expression of mutant HTT (Q93) in hemocytes did not directly affect the animal survival, but the numbers of circulating hemocytes were significantly decreased, leading to an impaired immune response against pat…”
BackgroundInfluentialInflammatory changes in peripheral organs in the BACHD murine model of Huntington's disease
Valadão, P. A. C., Oliveira, B. D. S., Joviano‐Santos, J. V., Vieira, É. L. M., Rocha, N. P., Teixeira, A. L., Guatimosim, C., & de Miranda, A. S. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116653 · Cited by 18 · cited 1×
“However the increased level of IL-6 was exhibited in kidney (43).”
BackgroundPodlacha, M., Pierzynowska, K., Gaffke, L., Jerzemowska, G., Piotrowska, E., & Węgrzyn, G. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100482 · Cited by 18 · cited 1×
“At early stages of disease, the anti-inflammatory defense mechanism was significantly impaired, with a marked decrease in IL-10 levels (42).”
BackgroundBai, D., Yin, P., Zhang, Y., Sun, F., Chen, L., Li, L., Yan, S., Li, S., & Li, X. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab129 · Cited by 7 · cited 1×
“Quantification of the number of different types of cells revealed that the KI striatum had the most severe loss of NeuN-positive cells and the highest increase in glial cell numbers, which was not observed in the age-matched HD KI mouse (66, 67).”
BackgroundSelf-citationAuthor Correction: Laquinimod treatment in the R6/2 mouse model
Ellrichmann, G., Blusch, A., Fatoba, O., Brunner, J., Reick, C., Hayardeny, L., Hayden, M. R., Sehr, D. A., Winklhofer, K. F., Saft, C., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37926-4 · Cited by 2
Cited by
Adamu, A., Li, S., Gao, F., & Xue, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1347987 · Cited by 564
Self-citationIron imbalance in neurodegeneration
Levi, S., Ripamonti, M., Moro, A. S., & Cozzi, A. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02399-z · Cited by 203
STAT3 Signaling Pathway in Health and Disease
Samad, M. A., Ahmad, I., Hasan, A., Alhashmi, M. H., Ayub, A., Al-Abbasi, F. A., Kumer, A., & Tabrez, S. S. M. (2025) · MedComm · doi:10.1002/mco2.70152 · Cited by 171
“Persistent STAT3 activation in HD has been associated withincreasedneuroinflammation,ahallmarkofthedisease[131, 144].”
Innate immune activation in neurodegenerative diseases
Castro-Gomez, S., & Heneka, M. T. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.010 · Cited by 162
The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions
Kerkis, I., da Silva, Á. R. D. B. P., & Araldi, R. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1400533 · Cited by 114
Metadata
- Authors
- Jia, Q., Li, S., Li, X.-J., & Yin, P.
- Affiliations
- Jinan University (CN)
- Corresponding author
- Li, Xiao-Jiang
- Yin, Peng
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-12-22
- Volume
- 13
- Pages
- 1088124-1088124
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC9815700
- OpenAlex
- W4312188108
- Cited by
- 70
- References
- 118
- Citations by year
- 2026: 15 · 2025: 28 · 2024: 21 · 2023: 6
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (2021ZT09Y007, 32270564, 81830032, 202007030008, 31872779, 2018B030337001)
- Guangdong Science and Technology Department (202007030008, 81830032, 31872779, 2018B030337001, 2021ZT09Y007)
- Fundamental Research Funds for the Central Universities (21622113)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Keywords
- Huntington's disease, neuroinflammation, huntingtin, CAG repeat expansion, striatal degeneration, neurodegeneration mechanisms, immune response, clinical therapeutics
- MeSH terms
- Neuroinflammatory Diseases, Animals, Disease Models, Animal, Huntington Disease, Inflammation, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

